Ask a doctor about a prescription for LERCAPRESS 20 mg/10 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Lercapress 20 mg/10 mg film-coated tablets
enalapril maleate/lercanidipine hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack:
Lercapress is a fixed combination of an ACE inhibitor (enalapril) and a calcium channel blocker (lercanidipine), two medicines that lower blood pressure.
Lercapress is used to treat high blood pressure (hypertension) in adult patients whose blood pressure is not adequately controlled by enalapril 20 mg alone. Lercapress should not be used for the initial treatment of hypertension.
Do not take Lercapress:
Warnings and precautions
Consult your doctor or pharmacist before starting to take Lercapress:
If you are taking any of the following medicines, the risk of angioedema may be increased:
If you are taking any of the following medicines used to treat high blood pressure:
Your doctor may need to check your kidney function, blood pressure, and the amount of electrolytes (e.g., potassium) in your blood at regular intervals.
Also, see the information included under the heading “Do not take Lercapress”.
If you are going to undergo surgery or certain treatments soon
If you are going to undergo any of the following procedures, inform your doctor that you are taking Lercapress:
You should inform your doctor if you think you are (or might be) pregnant or if you are breastfeeding (see the section Pregnancy, breastfeeding, and fertility).
Children and adolescents
The safety and efficacy of Lercapress in children under 18 years have not been established.
Other medicines and Lercapress
Lercapress should not be taken with certain medicines.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including those obtained without a prescription. This is because when Lercapress is taken with other medicines, the effect of Lercapress or the other medicines may be altered, or certain side effects may occur more frequently.
In particular, tell your doctor or pharmacist if you are taking any of the following medicines:
Do not take Lercapress if you have taken or are currently taking sacubitril/valsartan, a medicine used to treat chronic heart failure in adults, as the risk of angioedema (rapid swelling of the throat) is increased.
If you are taking any of the following medicines, the risk of angioedema may be increased:
Your doctor may need to adjust your dose and/or take other precautions:
Taking Lercapress with food, drinks, and alcohol
Pregnancy, breastfeeding, and fertility
Pregnancy and fertility
You should inform your doctor if you think you are (or might be) pregnant. Your doctor will normally advise you to stop taking Lercapress before you become pregnant or as soon as you know you are pregnant and will recommend that you take another medicine instead of Lercapress. The use of Lercapress is not recommended in women who can become pregnant or at the start of pregnancy, and it should not be taken if you are pregnant for more than 3 months, as it can seriously harm the fetus if used after the third month of pregnancy.
Breastfeeding
Lercapress should not be taken during breastfeeding.
Driving and using machines
If you experience dizziness, weakness, or drowsiness with this medicine, you should not drive or operate machinery.
Lercapress contains lactose and sodium
If your doctor has told you that you have an intolerance to some sugars, contact your doctor before taking this medicine.
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; this is essentially “sodium-free”.
Follow exactly the instructions of administration of this medicine given to you by your doctor. If you are not sure, consult your doctor or pharmacist again.
Adults:unless your doctor has told you otherwise, the recommended dose is one tablet once a day, at the same time each day. The tablet should be taken preferably in the morning, at least 15 minutes before breakfast. The tablets should be swallowed whole with water. See “Taking Lercapress with food, drinks, and alcohol”.
Patient with kidney problems/elderly:your doctor will decide the dose of medicine that you should take, depending on how well your kidneys are working.
If you take more Lercapress than you should
Do not exceed the prescribed dose. If you have taken more than you should or in case of overdose, consult your doctor or pharmacist immediately, or call the Toxicology Information Service, telephone (91) 562 04 20, or go to the hospital immediately. Take the package and the leaflet of the medicine with you to the healthcare professional. A dose higher than the correct one may cause a significant drop in blood pressure and your heart may beat irregularly or faster.
If you forget to take Lercapress
If you stop taking Lercapress
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. This medicine may cause the following adverse effects:
Some adverse effects can be serious.
Tell your doctor immediately if you notice any of the following adverse effects:
An allergic reaction accompanied by swelling of the face, lips, tongue, or throat that can cause difficulty breathing or swallowing;
When you start taking Lercapress, you may feel weakness or dizziness, or notice that your vision becomes blurred; this is caused by a sudden drop in blood pressure, and if it occurs, it will be useful for you to lie down. If you are concerned, consult your doctor.
Adverse Effects Observed with Lercapress
Frequent (may affect up to 1 in 10 people)
Cough, feeling of dizziness, headache.
Uncommon (may affect up to 1 in 100 people)
Changes in blood parameter values, such as a decrease in platelet count, increase in blood potassium concentration, nervousness (anxiety), feeling of dizziness when standing up, vertigo, rapid heartbeat, rapid or irregular heartbeat (palpitations), sudden reddening of the face, neck, or upper chest (erythema), low blood pressure, abdominal pain, constipation, feeling sick (nausea), increase in liver enzyme levels, skin reddening, joint pain, increased urination frequency, feeling of weakness, fatigue, feeling of heat, ankle swelling.
Rare (may affect up to 1 in 1,000 people)
Anemia, allergic reactions, ringing in the ears (tinnitus), fainting, dry throat, sore throat, indigestion, salty sensation on the tongue, diarrhea, dry mouth, gum inflammation, allergic reaction with swelling of the face, lips, tongue, or throat that causes difficulty swallowing or breathing, skin rash, hives, nocturia, production of large amounts of urine, impotence.
Additional Adverse Effects Observed with Enalapril or Lercanidipine Alone
Enalapril
Very common (affects more than 1 in 10 people)
Blurred vision, feeling of dizziness, weakness or discomfort, and cough.
Frequent (affects less than 1 in 10 people)
Depression, headache, fainting (syncope), chest pain, dizziness due to low blood pressure, changes in heart rate, rapid heartbeats, angina, shortness of breath, alterations in taste, increase in blood creatinine levels (usually detected by analysis), high blood potassium levels, diarrhea, abdominal pain, fatigue, rash, allergic reaction with inflammation of the face, lips, tongue, or throat with difficulty swallowing or breathing.
Uncommon (affects less than 1 in 100 people)
Anemia (including aplastic anemia and hemolytic anemia), sudden drop in blood pressure, confusion, nervousness, somnolence or insomnia, sensation of pins and needles in the skin or numbness, myocardial infarction (possibly caused by very low blood pressure in certain high-risk patients, including those with coronary or cerebral blood supply problems), stroke (possibly due to very low blood pressure in high-risk patients), runny nose, sore throat and hoarseness, asthma associated with chest tightness, slowing of food movement through the intestine (ileus), pancreatitis, feeling sick (vomiting), indigestion, constipation, stomach irritation (gastric irritation), dry mouth, ulcer, anorexia, itching or hives, hair loss, renal function alteration, renal failure, increased sweating, high protein levels in urine (measured by analysis), muscle cramps, feeling of general discomfort, high temperature (fever), low blood sugar or sodium levels, high urea levels in blood (all measured by blood analysis), reddening, rapid or irregular heartbeats (palpitations), vertigo (feeling of dizziness), ringing in the ears (tinnitus), impotence.
Rare (affects less than 1 in 1,000 people)
Changes in blood parameter values, such as a decrease in white blood cell count, bone marrow depression, autoimmune diseases, strange dreams or sleep disorders, Raynaud's phenomenon (in which hands and feet can become intensely cold and turn white due to low blood flow), nasal inflammation, pneumonia, liver problems, such as decreased liver function, liver inflammation, jaundice (yellowing of skin or eyes), increase in liver enzyme or bilirubin levels (measured by blood analysis), erythema multiforme (red spots of different shapes that appear on the skin), Stevens-Johnson syndrome and toxic epidermal necrolysis (a severe skin condition in which the skin reddens and scales form, blisters or open sores form), exfoliative dermatitis/erythroderma (severe skin rash with scaling or peeling of skin), pemphigus (small blisters filled with fluid on the skin), decreased urine production, male breast enlargement (gynecomastia), inflamed glands in the neck, armpits, or groin, fluid accumulation or other substances in the lungs (as seen on X-rays), cheek, gum, tongue, lip, or throat inflammation.
Very rare (affects less than 1 in 10,000 people)
Intestinal inflammation (intestinal angioedema).
Frequency not known (cannot be estimated from available data)
Excessive production of antidiuretic hormone that causes fluid retention, leading to weakness, fatigue, or confusion.
A set of symptoms has been reported that may include one or more of the following: fever, blood vessel inflammation (serositis, vasculitis), muscle pain (myalgia, myositis), joint pain (arthralgia/arthritis). A rash, photosensitivity, or other skin manifestations may occur.
Lercanidipine
Some of these adverse effects can be serious. If you experience any of these adverse effects, consult your doctor.
Rare (affects less than 1 in 1,000 people)
Chest pain (pain in the chest caused by lack of blood supply to the heart), allergic reactions (with symptoms such as itching, rash, hives), fainting.
Patients with pre-existing angina pectoris may experience an increase in frequency, duration, or severity of attacks associated with treatment with the group of medicines to which lercanidipine belongs. Isolated cases of myocardial infarction may be observed.
Other possible adverse effects:
Frequent (may affect up to 1 in 10 people): headache, rapid or irregular heartbeats (palpitations), sudden reddening of the face, neck, or upper chest, ankle swelling.
Uncommon (may affect up to 1 in 100 people): dizziness, low blood pressure, heartburn, discomfort, stomach pain, skin rash, itching, muscle pain, increased urination, weakness or fatigue.
Rare (may affect up to 1 in 1,000 people): somnolence, vomiting, diarrhea, hives, increased urination frequency, chest pain.
Frequency not known (cannot be estimated from available data): gum swelling, changes in liver function (detected by blood analysis), cloudy fluid (when performing hemodialysis through a tube into the abdomen), swelling of the face, lips, tongue, or throat that can cause difficulty breathing or swallowing.
If any of the adverse effects worsen, or if you experience any type of adverse effect that does not appear in this leaflet, inform your doctor or pharmacist. You can consult your doctor or pharmacist for more information about adverse effects, as they have a more complete list of adverse effects.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the blister pack and on the packaging after CAD. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from light and moisture. Do not store above 25°C.
Medicines should not be disposed of through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Lercapress Composition
The active ingredients are enalapril maleate and lercanidipine hydrochloride.
Each film-coated tablet contains: 20 mg of enalapril maleate (equivalent to 15.29 mg of enalapril) and 10 mg of lercanidipine hydrochloride (equivalent to 9.44 mg of lercanidipine).
The other ingredients are:
Core: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate type A, povidone K30, sodium bicarbonate, and magnesium stearate.
Film coating: hypromellose 5 cP, titanium dioxide (E171), talc, macrogol 6000, yellow quinoline aluminum lake (E104), and yellow iron oxide (E172).
Appearance of the Product and Package Contents
Lercapress 20 mg/10 mg film-coated tablets are 8.5 mm, yellow, circular, and biconvex.
Lercapress 20 mg/10 mg is available in packs of 7, 14, 28, 30, 35, 42, 50, 56, 90, 98, and 100 tablets.
Not all pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Recordati Ireland, Ltd. Raheens East, Ringaskiddy Co. Cork - Ireland.
Local Representative:
Casen Recordati, S.L. Autovía de Logroño, km 13,300. 50180 Utebo (Zaragoza). Spain.
Manufacturer
RECORDATI Industria Chimica e Farmaceutica S.p.A. – Via Matteo Civitali 1 – I-20148 Milan, Italy
Doppel Farmaceutici S.r.l., Via Volturno 48, Quinto de’Stampi, 20089 Rozzano (MI), Italy
This medicine is authorized in the Member States of the EEA under the following trade names:
Germany Carmen ACE
Italy Atover
Spain Lercapress
Date of the last revision of this leaflet 07/2021
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of LERCAPRESS 20 mg/10 mg FILM-COATED TABLETS in October, 2025 is around 11.24 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for LERCAPRESS 20 mg/10 mg FILM-COATED TABLETS – subject to medical assessment and local rules.